{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:13:30Z","timestamp":1788556410946,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omta.2025.201662","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T16:08:27Z","timestamp":1766765307000},"page":"201662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global age-related seroprevalence for adeno-associated virus serotype 9 immunoglobulin G"],"prefix":"10.1016","volume":"34","author":[{"given":"Christophe","family":"Lo Bianco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rienk E.","family":"Jeeninga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline E.","family":"Vietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8130-9858","authenticated-orcid":false,"given":"Rudolf W.","family":"van Olden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2025.201662_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omta.2025.201662_bib2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/ijms25021050","article-title":"Delivery of adeno-associated virus vectors to the central nervous system for correction of single gene disorders","volume":"25","author":"Daci","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2025.201662_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.omta.2025.201662_bib4","series-title":"Zolgensma (Onasemnogene Abeparvovec-Xioi)","year":"2025"},{"key":"10.1016\/j.omta.2025.201662_bib6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40263-022-00941-1","article-title":"Onasemnogene abeparvovec: a review in spinal muscular atrophy","volume":"36","author":"Blair","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.omta.2025.201662_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase I ascending-dose study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omta.2025.201662_bib8","article-title":"Intrathecal onasemnogene abeparvovec in treatment-na\u00efve patients with spinal muscular atrophy: a phase 3, randomized controlled trial","author":"Proud","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2025.201662_bib9","article-title":"Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial","author":"Kwon","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2025.201662_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101344","article-title":"Adeno-associated virus serotype 9 antibodies in neonates and young children: Seroprevalence and kinetics","volume":"32","author":"van Olden","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2025.201662_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-Mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2025.201662_bib12","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.omta.2025.201662_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101273","article-title":"Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies","volume":"32","author":"Chhabra","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2025.201662_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-66546-4","article-title":"Seroprevalence of adeno-associated virus types 1, 2, 3, 4, 5, 6, 8, and 9 in a Basque cohort of healthy donors","volume":"14","author":"Navarro-Oliveros","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2025.201662_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omtm.2021.02.014","article-title":"Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec","volume":"21","author":"Day","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2025.201662_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1089\/hum.2024.233","article-title":"Prevalence of neutralizing antibodies to AAV2 and AAV9 in individuals with Niemann-Pick disease, type C1","volume":"36","author":"Mylvara","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2025.201662_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2025.199549","article-title":"Pre-existing Anti-AAV9 antibodies in the Chinese healthy and rare disease populations: Implications for gene therapy","volume":"354","author":"Zhao","year":"2025","journal-title":"Virus Res."},{"key":"10.1016\/j.omta.2025.201662_bib18","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.3390\/ijms24065579","article-title":"Prevalence of neutralizing antibodies against adeno-associated virus serotypes 1, 2, and 9 in non-injected Latin American patients with heart failure-ANVIAS Study","volume":"24","author":"Sierra-Delgado","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2025.201662_bib19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.omtm.2022.10.014","article-title":"The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs","volume":"27","author":"Kashiwakura","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2025.201662_bib20","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.3390\/ijms26115224","article-title":"Neutralizing antibodies: role in immune response and viral vector based gene therapy","volume":"26","author":"Tsaregorodtseva","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2025.201662_bib21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fimmu.2014.00446","article-title":"Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies","volume":"5","author":"Niewiesk","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2025.201662_bib22","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2025.201662_bib23","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2025.201662_bib24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/22143602251324857","article-title":"Quantification and comparison of anti-AAV9 and anti-AAVrh74 antibodies in plasma and human milk: Implications for AAV-based gene therapy candidacy","volume":"12","author":"Leon-Astudillo","year":"2025","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omta.2025.201662_bib25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1089\/hum.2021.243","article-title":"Higher seroprevalence of anti-adeno-associated viral vector neutralizing antibodies among racial minorities in the United States","volume":"33","author":"Khatri","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2025.201662_bib26","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2010.06.004","article-title":"Kinetics of maternal antibodies against rubella and varicella in infants","volume":"29","author":"Leuridan","year":"2011","journal-title":"Vaccine"}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X25000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X25000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:29:01Z","timestamp":1788553741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X25000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3117387X25000126"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2025.201662","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global age-related seroprevalence for adeno-associated virus serotype 9 immunoglobulin G","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2025.201662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201662"}}